New hope: drug combo aims to stop brain tumors in breast cancer patients

NCT ID NCT05323955

Ongoing Disease control Sponsor: Carey Anders, M.D. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug tucatinib to standard therapy (trastuzumab/pertuzumab or T-DM1) can prevent new or worsening brain metastases in people with advanced HER2+ breast cancer. About 48 participants who have stable disease elsewhere but a new brain tumor will receive the combination after local treatment like radiation. The goal is to see if this approach extends the time before brain tumors progress.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tucatinib (Tukysa) added to trastuzumab (Herceptin), pertuzumab (Perjeta), or T-DM1
What this could lead to: If it works, this could offer a new way to delay or prevent new brain metastases in patients with advanced HER2+ breast cancer.
What could go wrong: This is a small Phase 2 trial with only 48 participants, so results may not apply to everyone. Adding tucatinib may cause side effects like diarrhea or liver problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer breast cancer breast carcinoma HER2 positive breast carcinoma metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER BRAIN METASTASES HUMAN EPIDERMAL GROWTH FACTOR 2 POSITIVE CARCINOMA OF BREAST

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Providence Portland Medical Center

Portland, Oregon, 97213, United States
University of California San Francisco

San Francisco, California, 94158, United States
University of Michigan Health System

Ann Arbor, Michigan, 48109, United States
Washington University in St. Louis

St Louis, Missouri, 63130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.